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Objective: To assess lung cancer risk in SLE, relative to demographics, drug exposures, smoking, and 
disease activity.  
 
Methods: We analyzed data from 14 SLE cohorts. We calculated adjusted hazard ratio (HR) estimates 
for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and 
cumulative disease activity (mean adjusted SLE Disease Activity, SLEDAI, scores). This project was 
approved by the ethics boards of all participating institutions, including the institutional review board of 
the McGill University Health Centre. The ethics approval Number for the Cancer Risk study is GEN-06-
031. 
 
Results: Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 
59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung-cancer free SLE controls. 
The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1% of 
those without lung cancer. In adjusted models, the principal factors associated with lung cancer were 
ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively 
imprecise but did not point towards any drug exposures as strong lung cancer risk factors. 
 
Conclusion: We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug 
risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer 
risk factor in SLE. 
Abstract word count: 185 
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Introduction:  
Recent data have highlighted the increase in cancer in SLE over-all; lung cancer specifically is 
30-50% more common in SLE patients than their sex and age-matched counterparts.1 Our objective was 
to assess lung cancer risk in SLE, comparing SLE patients with and without lung cancer regarding 
demographics, drug exposures, and disease activity.  
 
Materials and Methods:  
 Since approximately 2000, we have been working with investigators from the Systemic Lupus 
International Collaborating Clinics (SLICC) and other research networks, to further elucidate cancer risk 
in SLE.  The current cohort analysis of lung cancer risk factors is based on 14 centres that were able to 
provide detailed information on drug use, disease activity, and other factors. These centres were 
Canadian (Halifax, Calgary, Montreal, Toronto, Winnipeg), American (Baltimore, Chicago, two in New 
York, San Francisco) centres abroad (Birmingham and London UK, Sweden, and Seoul Korea). At all 
these centres, cancer cases were determined on the basis of linkage of the patients to the appropriate 
tumor registries. We used Cox proportional hazards regression to calculate the hazard ratio (HR) for 
lung cancer risk in SLE, relative to their exposure in terms of demographics (sex, race/ethnicity, and 
age, as a continuous time-dependent variable), smoking status, and time-dependent medication 
exposures.   
 We also adjusted for time-dependent cumulative disease activity, captured using mean adjusted 
SLE Disease Activity Index (SLEDAI) scores, which involve calculating the area under the curve between 
two SLEDAI scores as the average of the values at those two visits, multiplied by the length of time between 
the two visits. All the calculated areas are then summed, and divided by the total length of the time period. 
The adjusted mean SLEDAI has the same units as SLEDAI, and is interpreted in the same way. The adjusted 
mean SLEDAI has been shown to be a valid measure of cumulative SLE activity over time2. To aid in 
interpretation, the mean adjusted SLEDAI score was categorized within quartiles. At one centre 
(University of California San Francisco), disease activity was captured only with self-report items.3 
Thus at this centre the variable for cumulative SLE disease activity was similarly categorized within 
quartiles. The time-dependent disease activity in our model reflected whether or not a patient had 
reached the highest quartile of cumulative disease activity. We also controlled for any prior record of 
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pulmonary fibrosis, based on the SLICC/ACR Damage Index, using a dichotomous time-dependent 
variable. This was done since it has been suggested that pulmonary fibrosis may predispose to lung 
cancer.4 
Time zero for the observation interval was SLE diagnosis, so that our analyses adjusted for SLE 
duration (with left-censoring for the time from SLE diagnosis to cohort entry, when relevant, to avoid 
immortal time bias5). The use of SLE duration as the time axis was chosen because our earlier work 
suggested that cancer risk in SLE depends on SLE duration, in a non-linear way.1 However, we did 
perform a sensitivity analysis where age was the time axis (and SLE duration was a model covariate). 
We included lung cancers occurring after entry into the lupus cohort and up to the time of cohort 
exit (defined by death, cancer event, or date of last visit). Patients who developed a cancer other than 
lung cancer during the observation interval, were right-censored at that time.  
Additionally, a sub-analysis was also performed for 6 centers where more precise, time-
dependent data on smoking exposure had been collected (Sweden, San Francisco, Montreal, Halifax, 
Toronto and Winnipeg), in order to measure the effect of smoking intensity (in terms of a dose-effect of 
pack-years). Those analyses included 11 cases of lung cancer and 724 cancer-free subjects. 
 
Results:  
Across all the SLE cohorts that participated in our study, 49 new lung cancer cases occurred and 
were included in our analyses. Compared to SLE controls without cancer (Table 1), persons with SLE 
with lung cancer cases were more likely to be white (84.8% versus 61.8% in non-lung cancer SLE 
controls), older at cohort entry (mean 51.2 and median 52.2 years; versus mean 38.2, median 36.8 years 
in controls) and male (20.4% of lung, 95% CI 10.2, 34.3 versus 9.2%, 95% CI 8.4, 10) of the remaining 
cohort). At cohort entry, the mean disease duration was similar, while the median disease duration in 
lung cancer cases was 1.1 years, versus 3.1 years in SLE patients that did not develop cancer. The vast 
majority (84.2%) of the lung cancer cases in SLE were ever-smokers at baseline, versus 40.1% of the 
SLE patients who did not develop lung cancer.  
Among lung cancer cases, 59.0% had high disease activity (that is, a disease activity within the 
highest quartile) at baseline (95% confidence interval, CI 42.1,74.4%), in contrast to only 40.8% (95% 
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CI 39.4, 42.3) of SLE patients that went on to remain free of lung cancer. The average SLE duration at time 
of lung cancer diagnosis was 14.2 years.    
Regarding the medication profiles in the SLE patients who developed lung cancer versus those 
who did not, none of the patients had been exposed to cyclophosphamide prior to a lung cancer. In both 
univariate and adjusted models (Table 2), the principal factors associated with lung cancer risk were 
ever smoking (at cohort entry) and current age. There was no definitive evidence for greater cancer risk 
in SLE patients with higher cumulative disease activity over time. The estimated adjusted effects of all 
drugs were relatively imprecise. In a sensitivity analysis using age as the time axis, the results were 
similar. 
In the sub-analyses, based on centers where pack-years had been measured, for smokers at cohort 
entry who went on to develop lung cancer, the median number of pack-years of smoking accumulated at 
baseline was 25 (mean 28.2, 95% CI 11.1, 45.2) pack-years, versus 8 (mean 11.9, 95% CI 10.9, 12.9) for 
smokers who remained cancer-free (n = 724). Adjusting for current age, there was an increase in the HR 
of lung cancer equal to 1.04 (95% CI 1.02, 1.05) for each additional pack-year.  
Discussion:  
Cancer is an important outcome for SLE patients6. In our analyses, we saw no clear evidence for 
drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. It 
is worth noting in particular that none of the lung cancer cases had a history of cyclophosphamide 
exposure.  Smoking appeared to be the most significant modifiable lung cancer risk factor in SLE. 
Among lung cancer cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of SLE 
patients that remained lung-cancer free. Adjusted analyses were consistent with a possible trend for 
greater cancer risk in subjects within the highest quartile of SLE activity but the confidence interval for 
both the unadjusted and adjusted HR estimates included the null value. In our sample, detailed smoking 
exposure was only available on 11 lung cancer patients and 724 controls. Fortunately, we were still able 
to show the expected dose-related effects, in this subgroup analysis.” 
Lung cancer is one of the most common malignancies in the general population, and the five-year 
survival associated with advanced stages of this disease is poor.  Lung cancer is in fact the second most 
common lung cancer to occur in SLE. Patients with SLE are at greater risk not only for developing lung 
cancer, but also for dying from it; previous analyses have suggested a standardized mortality ratio for 
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lung cancer of 2.3 (95% CI 1.6–3.0) in SLE versus the general population.7 It is thus very important to 
understand what drives lung cancer risk in systemic autoimmune rheumatic diseases such as SLE. 
According to data published by the SEER, adenocarcinoma is the most frequent histologic type of lung 
cancer in women and men (41% and 33%, respectively), followed by squamous cell carcinoma (15% 
and 24% in women and men respectively)8, 9. The remaining types (large cell, small cell and others) are 
roughly equal in males and in females (representing about 45% of the remaining cancer types. In the 
predominantly female SLE population, we have previously published that adenocarcinoma was indeed 
the most common carcinoma, making up half of the lung cancers in SLE, in males and in females. 
Squamous cell carcinoma was also the second most common histology type, and made up 27% of the 
lung cancer histology in female SLE patients, and 17% of the lung cancer histology in male patients. 
The percentage of squamous cell carcinomas in females with SLE is higher than the percent of this 
histologic type in general population of female lung cancers (15%; the 95% confidence interval for the 
difference between proportions is -0.02, 0.27 and thus just scarcely includes the null value). It is 
interesting that in our prior publication of lung cancer histology in SLE, there were no large cell lung 
cancers noted, while about 9% of lung cancers in the general population are large-cell carcinoma. 
In the general population, small cell and squamous cell carcinomas are nearly always associated 
with smoking10. Squamous cell carcinoma rates have been declining in males but gradually increasing in 
females, possibly related to the increasing number of females that smoked after the 1950’s11. A recent 
study published by the National Cancer Registry of Ireland calculated that from 1994 to 2009 the 
incidence of squamous cell lung carcinoma in women has increased by 1.3% annually. However, at the 
same time, the incidence of adenocarcinoma in women has increased by even more (6.5%) annually12,13. 
Thus, it is intriguing that there should be a higher than expected number of squamous cell cancers in 
female SLE patients, while the percentage of adenocarcinoma in SLE seems to be what is expected.   
We have recently reviewed the evidence to guide cancer screening in SLE14. There are no 
original research studies directly comparing cancer screening strategies in SLE, and most authors 
recommend that SLE patients adhere to general population screening measures Interestingly, the US 
Preventive Services Task Force recommended annual low-dose computed tomography of the chest for 
adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit 
within the past 15 years (based on Grade B evidence) 15. Admittedly, this has been contested by the 
American Academy of Family Physicians. Still, evidence suggests that women may be more susceptible 
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to the carcinogenic effects of smoking versus men.16 It seems reasonable that SLE patients with the 
specified smoking history follow local recommendations for cancer screening; this decision could be 
made by the patients’ primary care doctor, who is generally in charge of cancer screening. Regardless of 
screening, emphasizing the importance of smoking cessation in SLE is critical.  
In conclusion, smoking appears to be the most significant modifiable risk factor for lung cancer 
in SLE. For obvious reasons, those who care for SLE patients should continue to actively counsel 
tobacco cessation in patients who smoke. Additional studies may also help determine the relative 
distribution of stages of lung cancer in SLE and understand the reason for the increased mortality risk 
from lung cancer in SLE.   
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